RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease

Menée à partir d'échantillons de tissus hépatiques issus de 217 patients atteints d'une stéatose hépatique non alcoolique et menée à l'aide de modèles murins, cette étude met en évidence le rôle de la kinase RIPK3 dans la régulation du métabolisme lipidique, le processus inflammatoire et la carcinogenèse

Résumé en anglais

Objective : Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD.

Design : RIPK3 levels were evaluated in two large independent cohorts of patients with biopsy proven NAFLD diagnosis and correlated with clinical and biochemical parameters. Wild-type (WT) or Ripk3-deficient (Ripk3